Results from a phase 3, multicenter, noninferiority study of ravulizumab (ALXN1210) versus eculizumab (ECU) in adult patients (PTS) with paroxysmal nocturnal hemoglobinuria (PNH) naive to complement inhibitors (CI)

Authors
Category Primary study
ConferenceOncology Research and Treatment
Year 2018
This article has no abstract
Epistemonikos ID: 022800e85f42a3529c7a3de81b1fd5849a340dd8
First added on: Apr 29, 2026